ProCE Banner Activity

Selecting Therapy for Less Common Driver Mutations in Advanced Lung Cancer: MET, RET, ALK, ROS, NTRK

Slideset Download
Download these slides from a live webinar for the most recent data on optimal treatment approaches for patients with NSCLC that are positive for less common driver mutations, including MET, RET, ALK, ROS, and NTRK.

Released: June 05, 2022

Expiration: June 04, 2023

No longer available for credit.

Share

Faculty

Todd M. Bauer

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Turning Point Therapeutics Inc

Faculty Disclosure

Primary Author

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Todd M. Bauer, MD, has disclosed that he has received funds for research support paid to his institution from AbbVie, Aileron, Amgen, ARMO, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera, Clovis, Daiichi Sankyo, Deciphera, Five Prime, Foundation Medicine, Genentech/Roche, GlaxoSmithKline, Ignyta, Immunocore, Immunogen, Incyte, Jacobio, Janssen, Karyopharm, Kolltan, Leap, Lilly, Loxo, MabVax, MedImmune, Medpacto, Merck, Merrimack, Millennium, Mirati, Moderna, Novartis, Onyx, Pfizer, Peleton, Phosplatin Therapeutics, Principa Biopharma, Roche, Sanofi, Stemline, Takeda, and Top Alliance BioScience; consulting fees from Blueprint Medicines, Exelixis, Guardant Health, Ignyta, Lilly, Loxo, Merck, Moderna, and Pfizer; fees for non-CME/CE services from Astellas, AstraZeneca, Celgene, Clovis Oncology, EMD Serono, Genentech, Lilly, Merck, Novartis, Pharmacyclics, Pfizer, and Sysmex; and has served on a speakers’ bureau for Bayer.